Thanos Dimopoulos
@thanosdimop
Followers
2K
Following
1K
Media
222
Statuses
2K
Professor of Therapeutics, Hematology, Oncology National and Kapodistrian University of Athens. School of Medicine.
Joined August 2015
Details of this paradigm changing trial below. Trial published in @NEJM Dec 2024 to coincide with @ASH_hematology presentation @thanosdimop
Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24
@thanosdimop @NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial https://t.co/NMnjBytzQT Slides in thread
2
4
15
Daratumumab was earlier approved for high risk smoldering myeloma in Europe based on the same trial.
Daratumumab is approved in Europe for high risk smoldering myeloma. This is a big deal for the field and for patients. In the AQUILA trial, a finding that I want to highlight is that almost twice as many patients needed to start full therapy for active myeloma with observation
1
6
19
HISTORIC AND PARADIGM CHANGING: FDA approves daratumumab for high risk smoldering multiple myeloma based on the AQUILA trial— the FIRST ever treatment approved for this indication. Excellent news and thanks to @JNJInnovMed and the huge worldwide team of investigators for
8
71
249
#Myeloma Paper of the Day: Patient-reported outcomes from DREAMM-8 study (Bela/Pom/dex vs. Vel/Pom/dex) show greater proportion of pts in BelaMaf group had meaningful improvement (≥10 points) at most visits but more blurred vision (43%) & fatigue: https://t.co/xrFadWAjvv.
#mmsm
2
9
24
Σας προσκαλούμε με χαρά στην Επιστημονική Ογκολογική Διημερίδα που θα λάβει χώρα στο Νοσοκομείο ΙΑΣΩ στις 1-2 Νοεμβρίου 2025! https://t.co/OP4U8UaalC
@thanosdimop @MichalisLiontos
0
2
6
EV-P combo has completely transformed bladder cancer. Now, as NAT in cisplatin ineligible: pCR:48%, ���️EFS and OS. Limitation: few pts received adj NIVO in the control arm. But almost 50% pCR!!! @OncoAlert #ESMO25 @myESMO @HeSMO_X @PGrivasMDPhD @Uromigos
1
12
33
We provide our recommendations as well. Download or bookmark! @LeukemiaJnl Link to PDF:
0
6
11
Minutes_from_NationalConference_of_RomanianSocietyofHematology#in_cooperation_with_BalkanMyelomaStudyGroup(BMSG)#Bucharest_01st_05thOctober2025
0
3
10
At the completion of the 31th national conference of the Romanian Society of Hematology in Bucarest With colleagues of the Balkan Myeloma Study Group.We had a productive meeting focusing on plasma cell dyscrasias
1
4
29
At the 31th National Conference of the Romanian Society of Hematology.Honored to be the president of the conference along with Dr Daniel Coriu and to have with us distinguished speakers such as Dr Nikhil Munshi,Dr Nizar Bahlis,Dr Syed Abbas,Dr Jelena Bila,Dr Sorina Badelita.
1
5
31
Just out in the New England Journal of Medicine! Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM
https://t.co/vu9REOKBPS 5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and
22
261
886
After 30 years, today was my last day on the bone marrow transplant unit at Indiana University. I have had the privilege of working alongside some of the brightest, kindest and hardworking people during my tenure. Along with our patients, these doctors, nurses, pharmacists,
10
5
63
#Myeloma Paper of the Day: Comparison of autologous & allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia in Japan finds no significant OS difference between the groups (median 3.2 years w/ auto-HCT & 1.4 w. allo): https://t.co/61fd9W3klj.
#mmsm
1
10
34
AHOS 2025 morning session dedicated to multiple myeloma Pr Terpos presented the recent EHA EMN guidelines
0
4
27
#Myeloma Paper of the Day: Study of genomic landscape of IgM-MGUS & pts w/ stable or progressive asymptomatic #Waldenström macroglobulinemia finds CD79B, ARID1A and CREBBP more often mutated in progressers; MYD88L265 VAF also significantly higher: https://t.co/KelckNh9XS.
#mmsm
1
11
22
Opening remarks of the AHOS 2025 by Dr Saydam and Dr Terpos.Looking forward to an exciting 3 day meeting
0
2
21
2
52
145